G12.0
Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
Clinical Classification Guidelines
Medical Intelligence & Overview
Infantile spinal muscular atrophy, also known as Werdnig-Hoffmann disease, is a serious genetic disorder that affects muscle strength and movement in infants. Classified under ICD-10 code G12.0, this condition is characterized by progressive muscle weakness due to the degeneration of motor neurons in the spinal cord and brainstem. Typically appearing within the first six months of life, this form of spinal muscular atrophy is the most severe and often leads to early mortality. Recognizing the symptoms and understanding the underlying causes can help in managing the condition and providing appropriate medical support.
Causes & Symptoms
Clinical Causes: Genetic mutation in the SMN1 gene, which leads to a deficiency of survival motor neuron (SMN) protein Inheritance in an autosomal recessive pattern, meaning both parents carry the faulty gene No environmental factors are known to cause this disorder
Key Symptoms: Severe muscle weakness evident from birth Poor muscle tone (hypotonia), leading to floppy baby appearance Inability to suck or swallow effectively Weak cry and poor vocalization Limited or absent movement of limbs and trunk Difficulty breathing due to weakened respiratory muscles Delayed motor milestones, such as inability to sit or stand independently Fasciculations or involuntary twitching of muscles in some cases
Diagnostic & Treatment
Diagnosis Path: Genetic testing to identify mutations in the SMN1 gene Electromyography (EMG) to assess electrical activity in muscles Muscle biopsy to observe characteristic degenerative changes Blood tests to rule out other neuromuscular conditions
Treatment Protocols: Supportive care such as physical and occupational therapy to promote mobility and prevent contractures Nutritional support, including specialized feeding techniques or feeding tubes, to ensure adequate nutrition Respiratory support, which may involve ventilatory assistance or breathing therapies Use of medications like nusinersen or gene therapy drugs that target SMN protein deficiency, which have shown promise in some cases Regular monitoring by a multidisciplinary team, including neurologists, pulmonologists, and nutritionists
Clinical Advice & FAQs
Billing Guidance
Is G12.0 a billable ICD-10 code?
Yes, G12.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G12.0?
Clinical documentation must specify the nature of Infantile spinal muscular atrophy, type I [Werdnig-Hoffman] and any associated comorbidities for accurate reporting.
Cite this Clinical Reference